Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  Kikuchi, Koichi ^a   Saigusa, Daisuke ^b   Kanemitsu, Yoshitomi ^b   Matsumoto, Yotaro ^b   Thanai, Paxton ^c   Suzuki, Naoto ^b   Mise, Koki ^d   Yamaguchi, Hiroaki ^e   Nakamura, Tomohiro ^b   Asaji, Kei ^b   Mukawa, Chikahisa ^b   Tsukamoto, Hiroki ^b   Sato, Toshihiro ^e   Oikawa, Yoshitsugu ^a   Iwasaki, Tomoyuki ^a   Oe, Yuji ^b   Tsukimi, Tomoya ^f   Fukuda, Noriko N ^f   Ho, Hsin Jung ^a,b   Nanto Hara, Fumika ^a,b   Ogura, Jiro ^e   Saito, Ritsumi ^b   Nagao, Shizuko ^g   Ohsaki, Yusuke ^a   Shimada, Satoshi ^a   Suzuki, Takehiro ^a,b   Toyohara, Takafumi ^a   Mishima, Eikan ^a   Shima, Hisato ^a   Akiyama, Yasutoshi ^a   Akiyama, Yukako ^a   Ichijo, Mariko ^a   Matsuhashi, Tetsuro ^a,b   Matsuo, Akihiro ^a   Ogata, Yoshiaki ^a   Yang, Ching Chin ^a,b   Suzuki, Chitose ^a   Breeggemann, Matthew C ^h   Heymann, Jurgen ^h   Shimizu, Miho ⁱ   Ogawa, Susumu ^a   Takahashi, Nobuyuki ^b   Suzuki, Takashi ^a   Owada, Yuji ^a   Kure, Shigeo ^a   Mano, Nariyasu ^e   Soga, Tomoyoshi ^f   Wada, Takashi ⁱ   Kopp, Jeffrey B ^h   Fukuda, Shinji ^f,j,k,l   Hozawa, Atsushi ^b   Yamamoto, Masayuki ^b   Ito, Sadayoshi ^a   Wada, Jun ^d   Tomioka, Yoshihisa ^b   Abe, Takaaki ^a,b   more..

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c WATERS CORPORATION   (United States)

^d OKAYAMA UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY HOSPITAL   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g FUJITA HEALTH UNIVERSITY   (Japan)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ KANAZAWA UNIVERSITY   (Japan)

^j KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

^k UNIVERSITY OF TSUKUBA   (Japan)

^l JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 AZA TYROSINE; APOTRYPTOPHANASE; GENOMIC DNA; PHENYL SULFATE; RNA 16S; SULFUR ACID DERIVATIVE; TRYPTOPHANASE; TYROSINE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ORGANIC ANION TRANSPORTER; PHENYLSULFATE; SLCO4C1 PROTEIN, HUMAN; STREPTOZOCIN; SULFATE; TYROSINE PHENOL LYASE;

DIABETES; DISEASE INCIDENCE; MICROBIAL COMMUNITY; PHENOL; PHYSIOLOGICAL RESPONSE; PROTEIN; RODENT; SULFATE; TOXIN;

ADULT; AGED; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEROIDALES; CHOLESTEROL BLOOD LEVEL; CITROBACTER; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOTOXICITY; CYTOTOXICITY ASSAY; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DNA EXTRACTION; DRUG INDUCED DISEASE; DRUG UPTAKE; ELECTRON MICROSCOPY; ELECTROSPRAY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERWINIA; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE FLORA; LACTOBACILLALES; LIQUID CHROMATOGRAPHY; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; MULTICENTER STUDY; NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE PHOSPHORYLATION; PROTEINURIA; PROTEUS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE QUADRUPOLE MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UREA NITROGEN BLOOD LEVEL; VERY ELDERLY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; COMPLICATION; DOG; EXPERIMENTAL DIABETES MELLITUS; GENETICS; INSULIN DEPENDENT DIABETES MELLITUS; MDCK CELL LINE; METABOLISM; METABOLOMICS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PHYSIOLOGY; PODOCYTE; PROCEDURES; TRANSGENIC ANIMAL; URINE; YOUNG ADULT;

BACTERIA (MICROORGANISMS); MUS; RATTUS;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANIMALS; ANIMALS, GENETICALLY MODIFIED; COHORT STUDIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOGS; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MALE; METABOLOMICS; MICE; MICE, INBRED C57BL; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; PODOCYTES; RATS; STREPTOZOCIN; SULFURIC ACID ESTERS; TYROSINE PHENOL-LYASE; YOUNG ADULT;

EID: 85064911992     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-09735-4     Document Type: Article

References (70)

1. Ritz, E. & Orth, S. R. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 341, 1127–1133 (1999).
2. Fineberg, D., Jandeleit-Dahm, K. A. & Cooper, M. E. Diabetic nephropathy: diagnosis and treatment. Nat. Rev. Endocrinol. 9, 713–723 (2013).
3. Pavkov, M. E. et al. Early renal function decline in type 2 diabetes. Clin. J. Am. Soc. Nephrol. 7, 78–84 (2012).
4. Mikkaichi, T. et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc. Natl Acad. Sci. USA 101, 3569–3574 (2004).
5. Menni, C. et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 62, 4270–4276 (2013).
6. Toyohara, T. et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J. Am. Soc. Nephrol. 20, 2546–2555 (2009).
7. Wiklund, S. et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal. Chem. 80, 115–122 (2008).
8. Kanemitsu, Y. et al. Simultaneous quantitative analysis of uremic toxins by LC-MS/MS with a reversed-phase/cation-exchange/anion-exchange tri-modal mixed-mode column. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1068-1069, 1–8 (2017).
9. Sato, T., Mishima, E., Mano, N., Abe, T. & Yamaguchi, H. Potential drug interactions mediated by renal organic anion transporter OATP4C1. J. Pharmacol. Exp. Ther. 362, 271–277 (2017).
10. Mishima, E. et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 92, 634–645 (2017).
11. Brinkkoetter, P. T., Ising, C. & Benzing, T. The role of the podocyte in albumin filtration. Nat. Rev. Nephrol. 9, 328–336 (2013).
12. Gallo, L. A. et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci. Rep. 6, 26428 (2016).
13. Sakairi, T. et al. Conditionally immortalized human podocyte cell lines established from urine. Am. J. Physiol. Ren. Physiol. 298, F557–F567 (2010).
14. Edamatsu, T., Fujieda, A. & Itoh, Y. Phenyl sulfate, indoxyl sulfate and p-cresyl sulfate decrease glutathione level to render cells vulnerable to oxidative stress in renal tubular cells. PloS ONE 13, e0193342 (2018).
15. Itoh, Y., Ezawa, A., Kikuchi, K., Tsuruta, Y. & Niwa, T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal. Bioanal. Chem. 403, 1841–1850 (2012).
16. Che, R., Yuan, Y., Huang, S. & Zhang, A. Mitochondrial dysfunction in the pathophysiology of renal diseases. Am. J. Physiol. Renal Physiol. 306, F367–F378 (2014).
17. Matsuhashi, T. et al. Mitochonic acid 5 (MA-5) facilitates ATP synthase oligomerization and cell survival in various mitochondrial diseases. EBioMedicine 20, 27–38 (2017).
18. Jheng, H. F., et al. Dietary low-fat soy milk powder retards diabetic nephropathy progression via inhibition of renal fibrosis and renal inflammation. Mol. Nutr. Food Res. 61, 10.1002/mnfr.201600461 (2017).
19. Oe, Y. et al. Coagulation factor Xa and protease-activated receptor 2 as novel therapeutic targets for diabetic nephropathy. Arterioscler. Thromb. Vasc. Biol. 36, 1525–1533 (2016).
20. Mise, K. et al. Identification of novel urinary biomarkers for predicting renal prognosis in patients with type 2 diabetes by glycan profiling in a Multicenter Prospective Cohort Study: U-CARE Study 1. Diabetes Care 41, 1765–1775 (2018).
21. Hayek, S. S. et al. Soluble urokinase receptor and chronic kidney disease. N. Engl. J. Med. 373, 1916–1925 (2015).
22. Guthoff, M., et al. Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Sci. Rep. 7, 40627 (2017).
23. Hoshino, J. et al. A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PloS ONE 13, e0190923 (2018).
24. Parving, H. H. et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 69, 2057–2063 (2006).
25. Wang, Z. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585–1595 (2015).
26. Watkins, E. B. & Phillips, R. S. Inhibition of tyrosine phenol-lyase from Citrobacter freundii by 2-azatyrosine and 3-azatyrosine. Biochemistry 40, 14862–14868 (2001).
27. Watkins, E. B. & Phillips, R. S. Enzymatic synthesis of aza-l-tyrosines. Bioorg. Med. Chem. Lett. 11, 2099–2100 (2001).
28. Bertin, C. et al. Grass roots chemistry: meta-tyrosine, an herbicidal nonprotein amino acid. Proc. Natl Acad. Sci. USA 104, 16964–16969 (2007).
29. Mishima, E. et al. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J. Am. Soc. Nephrol. 26, 1787–1794 (2015).
30. Sato, E., et al. Impact of the oral adsorbent AST-120 on organ-specific accumulation of uremic toxins: LC-MS/MS and MS imaging techniques. Toxins 10, 10.3390/toxins10010019 (2017).
31. Kumagai, H., Yamada, H., Matsui, H., Ohkishi, H. & Ogata, K. Tyrosine phenol lyase. I. Purification, crystallization, and properties. J. Biol. Chem. 245, 1767–1772 (1970).
32. Phillips, R. S., Demidkina, T. V. & Faleev, N. G. The role of substrate strain in the mechanism of the carbon-carbon lyases. Bioorg. Chem. 57, 198–205 (2014).
33. Harris, A. P. & Phillips, R. S. Benzimidazole analogs of (L)-tryptophan are substrates and inhibitors of tryptophan indole lyase from Escherichia coli. FEBS J. 280, 1807–1817 (2013).
34. Kikuchi, K. et al. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 878, 1662–1668 (2010).
35. Yamamoto, S. et al. Continuous reduction of protein-bound uraemic toxins with improved oxidative stress by using the oral charcoal adsorbent AST-120 in haemodialysis patients. Sci. Rep. 5, 14381 (2015).
36. Macisaac, R. J., Ekinci, E. I. & Jerums, G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am. J. Kidney Dis. 63, S39–S62 (2014).
37. Parving, H. H., Persson, F. & Rossing, P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res. Clin. Pract. 107, 1–8 (2015).
38. Lorenzo, V., Saracho, R., Zamora, J., Rufino, M. & Torres, A. Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. Nephrol. Dial. Transplant. 25, 835–841 (2010).
39. Reidy, K., Kang, H. M., Hostetter, T. & Susztak, K. Molecular mechanisms of diabetic kidney disease. J. Clin. Invest. 124, 2333–2340 (2014).
40. MacIsaac, R. J., Ekinci, E. I. & Jerums, G. Progressive diabetic nephropathy. How useful is microalbuminuria?: contra. Kidney Int. 86, 50–57 (2014).
41. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
42. Kalantar-Zadeh, K. & Fouque, D. Nutritional management of chronic kidney disease. N. Engl. J. Med. 377, 1765–1776 (2017).
43. Niwa, T., Ise, M. & Miyazaki, T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am. J. Nephrol. 14, 207–212 (1994).
44. Konishi, K. et al. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res. Clin. Pract. 81, 310–315 (2008).
45. Ising, C. et al. Prohibitin-2 depletion unravels extra-mitochondrial functions at the kidney filtration barrier. Am. J. Pathol. 186, 1128–1139 (2016).
46. Suzuki, T. et al. Mitochonic acid 5 binds mitochondria and ameliorates renal tubular and cardiac myocyte damage. J. Am. Soc. Nephrol. 27, 1925–1932 (2016).
47. Zeier, M. & Reiser, J. suPAR and chronic kidney disease-a podocyte story. Pflug. Arch. 469, 1017–1020 (2017).
48. Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60 (2012).
49. Vaziri, N. D., Zhao, Y. Y. & Pahl, M. V. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol. Dial. Transplant. 31, 737–746 (2016).
50. Vaziri, N. D. et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol. Dial. Transpl. 27, 2686–2693 (2012).
51. Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481 (2008).
52. Mishima, E. et al. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am. J. Physiol. Renal Physiol. 315, F824–F833 (2018).
53. Xu, K. Y. et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci. Rep. 7, 1445 (2017).
54. Kageyama, A. & Benno, Y. Catenibacterium mitsuokai gen. nov., sp. nov., a gram-positive anaerobic bacterium isolated from human faeces. Int. J. Syst. Evol. Microbiol. 50(Pt 4), 1595–1599 (2000).
55. Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15, 382–392 (2014).
56. Bone, E., Tamm, A. & Hill, M. The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am. J. Clin. Nutr. 29, 1448–1454 (1976).
57. McDonald, T. A., Holland, N. T., Skibola, C., Duramad, P. & Smith, M. T. Hypothesis: phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia. Leukemia 15, 10–20 (2001).
58. Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451–1463 (2013).
59. Saito, M. et al. N-hexacosanol ameliorates streptozotocin-induced diabetic rat nephropathy. Eur. J. Pharmacol. 544, 132–137 (2006).
60. Lopes, J. A. et al. Evaluation of pre-implantation kidney biopsies: comparison of Banff criteria to a morphometric approach. Kidney Int. 67, 1595–1600 (2005).
61. Shima, H. et al. A novel indole compound MA-35 attenuates renal fibrosis by inhibiting both TNF-alpha and TGF-beta1 pathways. Sci. Rep. 7, 1884 (2017).
62. Horio, M., Imai, E., Yasuda, Y., Watanabe, T. & Matsuo, S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am. J. Kidney Dis. 56, 32–38 (2010).
63. Kropelin, T. F. et al. Determining the optimal protocol for measuring an albuminuria class transition in clinical trials in diabetic kidney disease. J. Am. Soc. Nephrol. 27, 3405–3412 (2016).
64. Schmieder, R. E. et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J. Am. Soc. Nephrol. 22, 1353–1364 (2011).
65. Kim, S. W. et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res. 20, 241–253 (2013).
66. Magoc, T. & Salzberg, S. L. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27, 2957–2963 (2011).
67. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).
68. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple. Test. J. R. Stat. Soc. Ser. B 57, 289–300 (1995).
69. Ihaka, R. & Gentleman, R. R. A language for data analysis and graphics. J. Comput. Graph. Stat. 5, 299–314 (1996).
70. Morino, Y. & Snell, E. Tryptophanase (Escherichia coli B). Methods Enzymol. 17 (Part A), 439–446 (1970).